CeriBell’s (CBLL) “Buy” Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of CeriBell (NASDAQ:CBLL) in a report released on Tuesday morning,Benzinga reports. They currently have a $28.00 target price on the stock.

Several other research firms have also recently weighed in on CBLL. Canaccord Genuity Group dropped their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, CeriBell currently has a consensus rating of “Moderate Buy” and an average target price of $22.00.

CeriBell Stock Performance

NASDAQ CBLL opened at $23.25 on Tuesday. The stock has a market cap of $892.34 million, a PE ratio of -13.21 and a beta of 0.81. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The firm has a 50-day moving average of $18.83 and a 200-day moving average of $19.08. CeriBell has a 52-week low of $10.85 and a 52-week high of $24.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 43.02% and a negative net margin of 64.73%.The company had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. On average, sell-side analysts anticipate that CeriBell will post -1.89 EPS for the current year.

Insider Activity at CeriBell

In other news, CTO Raymond Woo sold 1,966 shares of CeriBell stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $35,388.00. Following the completion of the sale, the chief technology officer directly owned 195,682 shares in the company, valued at approximately $3,522,276. The trade was a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Tpg Gp A, Llc sold 202,368 shares of the stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $20.12, for a total value of $4,071,644.16. Following the sale, the insider directly owned 3,765,054 shares in the company, valued at $75,752,886.48. This represents a 5.10% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 300,685 shares of company stock valued at $5,935,326. 17.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its position in CeriBell by 6,424.8% during the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after purchasing an additional 374,179 shares during the period. Rhumbline Advisers increased its holdings in CeriBell by 109.9% in the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after buying an additional 17,177 shares during the period. New York State Common Retirement Fund raised its position in shares of CeriBell by 148.6% in the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after buying an additional 5,200 shares in the last quarter. Quantbot Technologies LP lifted its holdings in shares of CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after acquiring an additional 6,401 shares during the period. Finally, Invesco Ltd. acquired a new stake in shares of CeriBell during the 2nd quarter worth approximately $197,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.